XSWX
TECN
Market cap3.64bUSD
Oct 09, Last price
235.00CHF
1D
2.44%
1Q
28.49%
Jan 2017
47.89%
IPO
43.29%
Name
Tecan Group AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tecan Group AG delivers advanced laboratory instruments and complete solutions to a diverse client base, including pharmaceutical and biotechnology companies, academic research institutions, and both forensic and diagnostic laboratories. The company operates through two primary segments: Life Sciences Business and Partnering Business. Its comprehensive product range features liquid handling and automation systems, microplate readers and washers, various consumables, next-generation sequencing (NGS) reagents, immunoassays, microbodies, and specialized software. Key offerings include Tecan Laberwax, an innovative automation solution, and Resolvex, an intelligent sample preparation system utilized in fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions. Furthermore, Tecan develops and manufactures essential components like precision pumps, valves, robotic arms, and developer software, supplying these to other laboratory instrument manufacturers for use in life science research, diagnostics, and other industries. Its automation portfolio also includes platforms like Synergence and renowned instruments such as Freedom EVO and Fluent. With a global presence, Tecan Group AG conducts operations across Switzerland, Europe, North America, Asia, and other international markets. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.
Related entities
Subsidiaries (2)
Tecan Sales International GmbH
Tecan Trading AG
Key people
Ulrich Kanter
Executive Vice President, Head of the Division Development and Operations, Member of the Management Board · since 2014
Martin Braendle
Vice President, Communications & Investor Relations · since 2017
Ralf Griebel
Member of the Management Board and Head of the Partnering Business Division · since 2020
Klaus Lun
Executive Vice President, Head of the Life Sciences Business Division, Member of the Management Board · since 2017
Tania Micki
Chief Financial Officer, Member of the Management Board · since 2020
Markus Schmid
Executive Vice President, Head of Corporate Human Resources & Internal Communications, Member of the Management Board · since 2011
Andreas Wilhelm
Executive Vice President General Counsel and Secretary of the Board of Directors, Member of the Management Board · since 2012
Non-Executive Director · since 2015
Karen Huebscher
Non-Executive Director · since 2012
Gerard Vaillant
Non-Executive Director · since 2012
Non-Executive Independent Director · since 2011
Non-Executive Independent Director · since 2013
Headquarters & legal address
Seestrasse 103
Männedorf, ZH 8708
CH
Männedorf, ZH 8708
CH
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||